Patents Assigned to Neuralab Limited
-
Publication number: 20090297511Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide, active fragments thereof or an antibody thereto.Type: ApplicationFiled: December 4, 2008Publication date: December 3, 2009Applicant: Neuralab LimitedInventor: Dale B. Schenk
-
Patent number: 7189819Abstract: The invention provides improves agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.Type: GrantFiled: December 6, 2001Date of Patent: March 13, 2007Assignees: Wyeth, Neuralab LimitedInventors: Guriq Basi, Jose William Saldanha
-
Patent number: 7179892Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.Type: GrantFiled: March 12, 2003Date of Patent: February 20, 2007Assignees: Neuralab Limited, WyethInventors: Guriq Basi, Jose William Saldanha
-
Publication number: 20060280743Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.Type: ApplicationFiled: April 28, 2006Publication date: December 14, 2006Applicants: Neuralab Limited, WyethInventors: Guriq Basi, Jose Saldanha
-
Publication number: 20060121038Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.Type: ApplicationFiled: July 12, 2004Publication date: June 8, 2006Applicant: Neuralab LimitedInventors: Dale Schenk, Frederique Bard, Theodore Yednock
-
Patent number: 7014855Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: GrantFiled: March 31, 2004Date of Patent: March 21, 2006Assignee: Neuralab LimitedInventor: Dale B. Schenk
-
Publication number: 20060034858Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: ApplicationFiled: October 7, 2005Publication date: February 16, 2006Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20060029611Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: ApplicationFiled: October 7, 2005Publication date: February 9, 2006Applicant: Neuralab LimitedInventor: Dale Schenk
-
Patent number: 6982084Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: GrantFiled: March 31, 2004Date of Patent: January 3, 2006Assignee: NeuraLab LimitedInventor: Dale B. Schenk
-
Patent number: 6972127Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: GrantFiled: September 2, 2004Date of Patent: December 6, 2005Assignee: Neuralab LimitedInventor: Dale B. Schenk
-
Publication number: 20050255122Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: ApplicationFiled: September 2, 2004Publication date: November 17, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20050249727Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide, active fragments thereof or an antibody thereto.Type: ApplicationFiled: August 20, 2004Publication date: November 10, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Patent number: 6962707Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: GrantFiled: July 1, 2004Date of Patent: November 8, 2005Assignee: Neuralab LimitedInventor: Dale B. Schenk
-
Patent number: 6946135Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A?, peptide or an antibody thereto.Type: GrantFiled: September 2, 2004Date of Patent: September 20, 2005Assignee: Neuralab LimitedInventor: Dale B. Schenk
-
Publication number: 20050191292Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide, active fragments thereof or an antibody thereto.Type: ApplicationFiled: August 20, 2004Publication date: September 1, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20050191314Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: ApplicationFiled: April 15, 2005Publication date: September 1, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Patent number: 6936246Abstract: Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.Type: GrantFiled: November 28, 2000Date of Patent: August 30, 2005Assignee: Neuralab LimitedInventor: Dale B. Schenk
-
Patent number: 6923964Abstract: Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.Type: GrantFiled: June 1, 2000Date of Patent: August 2, 2005Assignee: Neuralab LimitedInventor: Dale B. Schenk
-
Publication number: 20050163788Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: ApplicationFiled: September 2, 2004Publication date: July 28, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20050158304Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.Type: ApplicationFiled: July 12, 2004Publication date: July 21, 2005Applicant: Neuralab LimitedInventors: Dale Schenk, Frederique Bard, Theodore Yednock
